Shanghai Biobond Pharmaceutical Co. Ltd was registered and established in June 2013, located in the eastern area of Zhangjiang High tech Park (National Medical Device Park) in Shanghai. Invested by several senior Chinese pharmacologists, it was founded based on the first-class research conditions and screening platform of the Chinese Academy of Sciences. The company is mainly committed to the research of new drugs in the fields of nerve pain, anti-tumor, and drug-resistant new antibiotics. The main management personnel of the company have rich company management experience, profound background in new drug research and development technology, and rich experience in new drug research and development; The main research and development team consists of professionals in synthesis, pharmacology, formulation, analysis, and other fields. Currently, there is one academician, two professors, multiple doctoral and master's degrees. The company's main business direction is "overall solution solution" for generic drug research, technical public relations, and new drug research. The "overall solution" and technical public relations of generic drug research: The so-called overall solution is to help enterprises complete a complete set of generic drug research, including a complete set of preclinical pharmaceutical research. Pre clinical pharmaceutical research refers to the study of raw materials, preparation processes, and the quality of each stage in accordance with the registration and application requirements. Complete the complete set of application materials and assist pharmaceutical companies in completing the application and registration of drugs. At present, the cooperating enterprises include well-known domestic pharmaceutical companies such as Yangzijiang and Hainan Haiyao. New drug research: Mainly relying on the "International Scientist Workstation for Neuropharmacology Research" of the Shanghai Institute of Pharmacy, the screening platform for anti-tumor drugs, and the screening platform for new antibiotics against drug-resistant bacteria, we conduct research on drug design, synthesis, and screening. At present, candidate drugs have been screened in all three directions and comprehensive preclinical research is underway. The company has made good progress in new types of Olaparib derivatives, Ivolimus derivatives, Pregabalin derivatives, and Linazolamide derivatives; We have applied for 9 invention patents and authorized 5. The company successfully introduced equity risk strategic investment in 2017 and conducted a good evaluation of its past work, achieving a valuation of over 100 million yuan, laying a solid foundation for the company's further development.
Production Base
The production base is located in Yanjia Chemical Industry Park, Chongqing, covering an area of over 60 acres. The production workshop covers an area of over 12000 square meters, including a GMP purification area of over 1800 square meters. Currently, it has 120 employees. Capable of undertaking conventional reactions, low-temperature reactions (minimum reaction temperature -70 ℃), high-pressure hydrogenation reactions, high vacuum distillation, etc., equipped with purified water systems, liquid nitrogen cooling systems, three-level Roots vacuum systems, and sewage treatment systems. One production line for granules, tablets, and capsules, with a production capacity of 1.6 billion tablets (bags) per year.
Research and Developent Center
The company's research center is located in Zhangjiang Science and Technology Park (East Zone) and National Medical Device Park in Pudong New Area. Technical personnel have years of experience in drug synthesis, formulation, analytical quality, and process development, with a doctoral and master's degree ratio of over 50% in various disciplines of pharmacy. Capable of completing new drug research such as drug molecular design, synthesis, and screening, while also conducting drug research and development for "me too" and "me better" based on the latest newly launched or clinically active new drugs from major pharmaceutical companies worldwide. Able to complete the technical development work of various scales required for the synthesis process and formulation process of drugs, from small and medium-sized trials to industrial production. Technology Outsourcing
1. CRO:
a. Conduct various reactions
Temperature from -78 ℃ to 250 ℃
Pressure from 1 atm To 100 atm
And other conditions
b. Customized quantity from 1 mg to 100 g by CRO
2. CMO
a. GMP factory building
b. Fixed mass from 100 g to 100kg
Technology Service
Research on the preclinical "overall plan" of raw materials and preparations
Pre clinical research of APIs and overall solutions
a. Process research
Including small-scale, pilot, and large-scale production of raw material drug synthesis
Small scale, pilot scale, and large-scale production of preparation technology
b. Related substance research
c. Quality research
d. Study on Drug Stability
